EP3618819A4 - Targeted drug rescue with novel compositions, combinations, and methods thereof - Google Patents
Targeted drug rescue with novel compositions, combinations, and methods thereof Download PDFInfo
- Publication number
- EP3618819A4 EP3618819A4 EP18794381.6A EP18794381A EP3618819A4 EP 3618819 A4 EP3618819 A4 EP 3618819A4 EP 18794381 A EP18794381 A EP 18794381A EP 3618819 A4 EP3618819 A4 EP 3618819A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- combinations
- methods
- novel compositions
- targeted drug
- drug rescue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762501696P | 2017-05-04 | 2017-05-04 | |
PCT/US2017/048748 WO2018039642A1 (en) | 2016-08-26 | 2017-08-25 | Compositions and methods thereof |
TW106129169A TW201815387A (en) | 2016-08-26 | 2017-08-28 | Compositions and methods thereof |
US201862634162P | 2018-02-22 | 2018-02-22 | |
US201862635554P | 2018-02-27 | 2018-02-27 | |
US201862636099P | 2018-02-27 | 2018-02-27 | |
US201862636171P | 2018-02-28 | 2018-02-28 | |
PCT/US2018/030978 WO2018204713A1 (en) | 2017-05-04 | 2018-05-03 | Targeted drug rescue with novel compositions, combinations, and methods thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3618819A1 EP3618819A1 (en) | 2020-03-11 |
EP3618819A4 true EP3618819A4 (en) | 2021-01-20 |
Family
ID=65431106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18794381.6A Pending EP3618819A4 (en) | 2017-05-04 | 2018-05-03 | Targeted drug rescue with novel compositions, combinations, and methods thereof |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP3618819A4 (en) |
JP (2) | JP2020518617A (en) |
KR (2) | KR20200062078A (en) |
CN (1) | CN110831584B (en) |
AU (2) | AU2018261654A1 (en) |
BR (1) | BR112019022902A2 (en) |
CA (2) | CA3138116A1 (en) |
IL (1) | IL270326B2 (en) |
MA (1) | MA49464A (en) |
RU (1) | RU2760558C9 (en) |
TW (1) | TWI787260B (en) |
WO (1) | WO2018204713A1 (en) |
ZA (1) | ZA201908006B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3941469A4 (en) * | 2019-03-18 | 2022-05-18 | Avanir Pharmaceuticals, Inc. | Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine |
CN115667217A (en) | 2020-05-19 | 2023-01-31 | 赛本爱尔兰有限公司 | Deuterated tryptamine derivatives and methods of use |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004006930A1 (en) * | 2002-07-17 | 2004-01-22 | Avanir Pharmaceuticals | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
WO2014011590A2 (en) * | 2012-07-12 | 2014-01-16 | Javitt Daniel C | Composition and method for treatment of depression and psychosis in humans |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4241065A (en) * | 1979-07-02 | 1980-12-23 | E. I. Du Pont De Nemours And Company | Fluoro analogs of hydrocodone and oxycodone useful as analgesics, narcotic antagonists or both |
US4950658A (en) * | 1988-12-06 | 1990-08-21 | Board Of Trustees Of Southern Illinois Univ. | Method of medical treatment of Alzheimer's disease |
US5891885A (en) * | 1996-10-09 | 1999-04-06 | Algos Pharmaceutical Corporation | Method for treating migraine |
US6207674B1 (en) * | 1999-12-22 | 2001-03-27 | Richard A. Smith | Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants |
US6335371B1 (en) * | 2000-11-28 | 2002-01-01 | Orion Corporation | Method for inducing cognition enhancement |
US20070099947A1 (en) * | 2005-11-03 | 2007-05-03 | Alkermes, Inc. | Methods and compositions for the treatment of brain reward system disorders by combination therapy |
EP2162135A4 (en) * | 2007-05-21 | 2012-02-22 | Reviva Pharmaceuticals Inc | Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents |
US8017623B2 (en) * | 2008-07-03 | 2011-09-13 | Trinity Laboratories, Inc. | Dextromethorphan hydrochloride |
CN105491885B (en) * | 2013-03-07 | 2018-09-25 | 思想实验室有限责任公司 | Pain medication combination and application thereof |
AU2014232869A1 (en) * | 2013-03-15 | 2015-10-08 | Patrizia Fanara | Methods for monitoring the effects of an agent in sujects with motoneuron disease with dementia |
WO2018039642A1 (en) * | 2016-08-26 | 2018-03-01 | Exciva Ug (Haftungsbeschränkt) | Compositions and methods thereof |
-
2018
- 2018-05-03 CN CN201880037396.3A patent/CN110831584B/en active Active
- 2018-05-03 BR BR112019022902A patent/BR112019022902A2/en active Search and Examination
- 2018-05-03 AU AU2018261654A patent/AU2018261654A1/en not_active Abandoned
- 2018-05-03 EP EP18794381.6A patent/EP3618819A4/en active Pending
- 2018-05-03 KR KR1020197035796A patent/KR20200062078A/en not_active Application Discontinuation
- 2018-05-03 MA MA049464A patent/MA49464A/en unknown
- 2018-05-03 CA CA3138116A patent/CA3138116A1/en active Pending
- 2018-05-03 JP JP2019560216A patent/JP2020518617A/en active Pending
- 2018-05-03 CA CA3062452A patent/CA3062452C/en active Active
- 2018-05-03 RU RU2019137004A patent/RU2760558C9/en active
- 2018-05-03 KR KR1020217033764A patent/KR102444803B1/en active IP Right Grant
- 2018-05-03 WO PCT/US2018/030978 patent/WO2018204713A1/en active Application Filing
- 2018-05-04 TW TW107115320A patent/TWI787260B/en active
-
2019
- 2019-10-31 IL IL270326A patent/IL270326B2/en unknown
- 2019-12-02 ZA ZA2019/08006A patent/ZA201908006B/en unknown
-
2021
- 2021-08-13 AU AU2021215274A patent/AU2021215274B2/en active Active
-
2023
- 2023-07-21 JP JP2023119151A patent/JP2023143940A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004006930A1 (en) * | 2002-07-17 | 2004-01-22 | Avanir Pharmaceuticals | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
WO2014011590A2 (en) * | 2012-07-12 | 2014-01-16 | Javitt Daniel C | Composition and method for treatment of depression and psychosis in humans |
Non-Patent Citations (3)
Title |
---|
DOO-YEOUN CHO ET AL: "Selective Inhibition of Cytochrome P450 2D6 by Sarpogrelate and Its Active Metabolite, M-1, in Human Liver Microsomes", DRUG METABOLISM AND DISPOSITION, vol. 42, no. 1, 28 October 2013 (2013-10-28), US, pages 33 - 39, XP055674658, ISSN: 0090-9556, DOI: 10.1124/dmd.113.054296 * |
MEIJUAN XU ET AL: "Effect of sarpogrelate hydrochloride on cytochrome P450 2D1/2 in rats", vol. 30, no. 12, 1 January 2014 (2014-01-01), pages 1739 - 1742, XP009519281, ISSN: 1001-1978, Retrieved from the Internet <URL:http://wprim.whocc.org.cn/admin/article/articleDetail?WPRIMID=458713&articleId=458713> DOI: 10.3969/J.ISSN.1001-1978.2014.12.024 * |
SOO KYUNG BAE ET AL: "Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humans", DRUG DESIGN, DEVELOPMENT AND THERAPY, vol. Volume 10, 1 September 2016 (2016-09-01), pages 2959 - 2972, XP055674632, DOI: 10.2147/DDDT.S109141 * |
Also Published As
Publication number | Publication date |
---|---|
AU2021215274B2 (en) | 2022-11-03 |
RU2760558C9 (en) | 2022-02-22 |
TWI787260B (en) | 2022-12-21 |
IL270326B (en) | 2022-10-01 |
KR20200062078A (en) | 2020-06-03 |
IL270326A (en) | 2018-05-03 |
MA49464A (en) | 2020-04-29 |
BR112019022902A2 (en) | 2020-05-19 |
TW201842902A (en) | 2018-12-16 |
EP3618819A1 (en) | 2020-03-11 |
RU2019137004A (en) | 2021-06-04 |
CA3062452A1 (en) | 2018-11-08 |
CN110831584A (en) | 2020-02-21 |
KR20210130827A (en) | 2021-11-01 |
CA3138116A1 (en) | 2018-11-08 |
AU2021215274A1 (en) | 2021-09-02 |
CN110831584B (en) | 2023-03-10 |
WO2018204713A1 (en) | 2018-11-08 |
KR102444803B1 (en) | 2022-09-19 |
RU2019137004A3 (en) | 2021-06-04 |
ZA201908006B (en) | 2021-04-28 |
AU2018261654A1 (en) | 2019-11-14 |
CA3062452C (en) | 2023-10-24 |
JP2023143940A (en) | 2023-10-06 |
RU2760558C2 (en) | 2021-11-29 |
IL270326B2 (en) | 2023-02-01 |
JP2020518617A (en) | 2020-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3463386A4 (en) | Oligonucleotides, compositions and methods thereof | |
EP3665156A4 (en) | Compounds, compositions and methods | |
EP3313404A4 (en) | Therapeutic compositions, combinations, and methods of use | |
EP3485068A4 (en) | Electrochemical methods, devices and compositions | |
EP3315608A4 (en) | Sirna, pharmaceutical composition and conjugate which contain sirna, and uses thereof | |
EP3676297A4 (en) | Compounds, compositions and methods | |
EP3297637A4 (en) | Benzene-1,3,5-tricarboxamide derivatives and uses thereof | |
EP3313530A4 (en) | 4,6-pyrimidinylene derivatives and uses thereof | |
EP3161124A4 (en) | Endophytes, associated compositions, and methods of use thereof | |
EP3491026A4 (en) | Human antibodies, pharmaceutical compositions and methods | |
EP3100731A4 (en) | Ligand-cytotoxicity drug conjugate, preparation method therefor, and uses thereof | |
EP3137168A4 (en) | Substituted 4-phenylpiperidines, their preparation and use | |
EP3131131A4 (en) | Light-emission element, and composition used therein | |
EP3159344A4 (en) | Amino pyranoid ring derivative and composition and use thereof | |
EP3723763A4 (en) | Anti-cd22 antibody-maytansine conjugates, combinations, and methods of use thereof | |
EP3395366A4 (en) | Drug design method, obtained drug and application thereof | |
EP3381925A4 (en) | Deuterium-modified brigatinib derivatives, pharmaceutical compositions comprising same, and use thereof | |
EP3162835A4 (en) | Monomer composition, and curable composition including same | |
EP3359676A4 (en) | Transposon system, kit comprising the same, and uses thereof | |
EP3699179A4 (en) | Pyrazolyl-containing tricyclic derivative, preparation method therefor and use thereof | |
EP3449924A4 (en) | Composition, crocins active site, and uses thereof | |
EP3239183A4 (en) | Modified conjugated diene polymer, and polymer composition containing said polymer | |
ZA201908006B (en) | Targeted drug rescue with novel compositions, combinations, and methods thereof | |
EP3554504A4 (en) | Substituted pyrazole-pyrimidines, variants thereof, and uses therefore | |
EP3386988A4 (en) | Novel dihydropyranopyrimidinone derivatives, and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20191203 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
RAV | Requested validation state of the european patent: fee paid |
Extension state: MA Effective date: 20191203 Extension state: TN Effective date: 20191203 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40015233 Country of ref document: HK |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0031135000 Ipc: A61K0031138000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20201217 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/225 20060101ALI20201211BHEP Ipc: A61K 47/60 20170101ALI20201211BHEP Ipc: A61K 9/20 20060101ALI20201211BHEP Ipc: A61K 47/36 20060101ALI20201211BHEP Ipc: A61K 31/485 20060101ALI20201211BHEP Ipc: A61K 31/195 20060101ALI20201211BHEP Ipc: A61K 45/06 20060101ALI20201211BHEP Ipc: A61K 31/13 20060101ALI20201211BHEP Ipc: A61K 31/138 20060101AFI20201211BHEP Ipc: A61P 25/00 20060101ALI20201211BHEP Ipc: A61K 31/439 20060101ALI20201211BHEP Ipc: A61P 9/00 20060101ALI20201211BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20231123 |